TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22842835

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) for three months, twice a week, focusing on lower limb muscles
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 43
Study: 20542898

Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 mg, 2-4 hours prior to surgery)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 mg, 6-8 hours prior to surgery)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 mg, 6-8 hours prior to surgery)
Number of subjects: 141
Study: 18704361

Group type: EXPERIMENTAL
Intervention: Elastography-guided biopsy
Number of subjects: 351

Group type: COMPARATOR
Intervention: Classic TRUS-guided 10-core biopsy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Elastography in T1c subgroup
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Elastography prediction of histopathologic findings
Number of subjects: 351
Study: 17269558

Group type: EXPERIMENTAL
Intervention: Fish oil concentrate (6 g/d, 4.4 g of LCn‐3PUFA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (olive oil, 6 g/d)
Number of subjects: 17
Study: 12927008

Group type: EXPERIMENTAL
Intervention: Citalopram (20 to 40 mg/day) after 1 week of placebo for 2 months
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (ineffective treatment)
Number of subjects: 107
Study: 10730039

Group type: EXPERIMENTAL
Intervention: Double phototherapy (conventional phototherapy with special blue light plus fiberoptic phototherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional phototherapy (special blue lamps alone)
Number of subjects: 0
Study: 9042561

Group type: EXPERIMENTAL
Intervention: Prophylaxis with low molecular weight heparins for 1 month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional prophylaxis during hospitalisation
Number of subjects: 0
Study: 1643938

Group type: EXPERIMENTAL
Intervention: Alexander technique (AT) instruction
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 10
Study: 6397660

Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Actrapid HM, Novo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Purified pork insulin (Actrapid MC, Novo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both insulin preparations (HM and MC)
Number of subjects: 12
Study: 31479068

Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment for 3 weeks
Number of subjects: 127

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 127
Study: 30135248

Group type: EXPERIMENTAL
Intervention: hDPSC implantation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Apexification treatment
Number of subjects: 40
Study: 26933897

Group type: EXPERIMENTAL
Intervention: L-Carnitine 750 mg/day for 8 weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 72
Study: 25062520

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group program
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 160
Study: 22433323

Group type: EXPERIMENTAL
Intervention: Twin-block appliance with Southend clasp
Number of subjects: 52

Group type: COMPARATOR
Intervention: Twin-block appliance without Southend clasp
Number of subjects: 52
Study: 19280298

Group type: EXPERIMENTAL
Intervention: Cefotiam (CTM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 100
Study: 17365993

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic condition (plasma glucose = 15 mmol/L)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Euglycaemic condition (plasma glucose = 5 mmol/L)
Number of subjects: 9
Study: 16377949

Group type: EXPERIMENTAL
Intervention: Etizolam (3.0 mg per day for 14 days)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no medical treatment)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Low density of hematoma on CT
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Paresis as an initial symptom
Number of subjects: 53
Study: 11970777

Group type: EXPERIMENTAL
Intervention: Perceived control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived difficulty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived control and perceived difficulty
Number of subjects: 0
Study: 9813961

Group type: EXPERIMENTAL
Intervention: Transenvironmental programming (TP) + curriculum-based measurement (CBM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transenvironmental programming (TP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Curriculum-based measurement (CBM)
Number of subjects: 0
Study: 7906288

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 0
Study: 2670188

Group type: EXPERIMENTAL
Intervention: Oncology home care (OHC)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Standard home care (SHC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Office care (OC)
Number of subjects: 166
Study: 1071683

Group type: EXPERIMENTAL
Intervention: Hydrallazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 0
Study: 31710842

Group type: EXPERIMENTAL
Intervention: AI screening tool for detecting low EF
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20000
Study: 30246408

Group type: EXPERIMENTAL
Intervention: Reminiscence therapy applied once a week for 8 weeks, 60 minutes per session
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 28295134

Group type: EXPERIMENTAL
Intervention: REACH II
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: REACH VA
Number of subjects: 110
Study: 26265590

Group type: EXPERIMENTAL
Intervention: Enhanced Peer Support intervention
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 41
Study: 23331518

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (GARDASIL)
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study: 21173393

Group type: EXPERIMENTAL
Intervention: Training atypical examples in the category
Number of subjects: 6

Group type: COMPARATOR
Intervention: Training typical examples
Number of subjects: 6
Study: 18839054

Group type: EXPERIMENTAL
Intervention: PF-PPS infusions (100-100 mg/day) for 5 days
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 89
Study: 17719763

Group type: EXPERIMENTAL
Intervention: Tiotropium administered via pMDI and spacer
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tiotropium administered via DPI (Rotahaler)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Tiotropium (both pMDI and DPI)
Number of subjects: 19
Study: 15386563

Group type: COMPARATOR
Intervention: Bolus mitoxantrone (MTZ)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous infusion mitoxantrone (CI-MTZ)
Number of subjects: 40
Study: 11350501

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Combination of EMD and GTR
Number of subjects: 56

Group type: COMPARATOR
Intervention: Flap surgery (control)
Number of subjects: 56
Study: 9875045

Group type: EXPERIMENTAL
Intervention: High strength pancreatic enzyme preparations
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 7994797

Group type: EXPERIMENTAL
Intervention: Maximal androgen blockade (MAB) + epirubicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Castration + epirubicin or estramustine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (MPA) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MPA + epirubicin
Number of subjects: 0
Study: 2700237

Group type: EXPERIMENTAL
Intervention: 50% solution of dimethylsulforoxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physiotherapeutic methods (ultrasound and phonophoresis with analgin)
Number of subjects: 0
Study: 911606

Group type: EXPERIMENTAL
Intervention: Enteric coated tablets (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-enteric coated tablets (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone (10 mg)
Number of subjects: 0
Study: 29100765

Group type: EXPERIMENTAL
Intervention: Transosseous tunnels that breached the anterior cortex (PA)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Transosseous tunnels that did not breach the anterior cortex (TT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group with unmodified patellas
Number of subjects: 26
Study: 27403758

Group type: EXPERIMENTAL
Intervention: Robotic sacrocolpopexy
Number of subjects: 78

Group type: COMPARATOR
Intervention: Laparoscopic sacrocolpopexy
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both robotic and laparoscopic arms
Number of subjects: 78
Study: 24332890

Group type: EXPERIMENTAL
Intervention: Paroxetine (20mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 22539587

Group type: EXPERIMENTAL
Intervention: Oral octreotide 20 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Subcutaneous (sc) octreotide 100 μg
Number of subjects: 75
Study: 19896902

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 325

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 325
Study: 17493510

Group type: EXPERIMENTAL
Intervention: Zinc + Oral Rehydration Solution (ORS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Oral Rehydration Solution (ORS)
Number of subjects: 117
Study: 16037113

Group type: EXPERIMENTAL
Intervention: Mild hyperstimulation cycles
Number of subjects: 171

Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 171
Study: 12076842

Group type: EXPERIMENTAL
Intervention: LTG + PHT
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: LTG + CBZ
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Withdrawal of PHT
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Withdrawal of CBZ
Number of subjects: 156
Study: 10235613

Group type: EXPERIMENTAL
Intervention: ECP alone
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECP + 3 MIU IFN‐alpha2a
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECP + 6 MIU IFN‐alpha2a
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ECP + IFN‐alpha
Number of subjects: 15
Study: 8728219

Group type: EXPERIMENTAL
Intervention: Swan neck coiled catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Straight Tenckhoff catheter
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 2023770

Group type: EXPERIMENTAL
Intervention: Intrathecal baclofen infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Permanent programmable infusion pumps
Number of subjects: 9
Study: 6178497

Group type: EXPERIMENTAL
Intervention: Different dose fractionation irradiation schedules
Number of subjects: 90

Group type: COMPARATOR
Intervention: Administration of steroid or chemotherapy during the one‐month on‐study period
Number of subjects: 90
Study: 28135215

Group type: EXPERIMENTAL
Intervention: Low RT volume (3 sets for each exercise, n = 10)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High RT volume (6 sets for each exercise, n = 12)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (CT, n = 12)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low RT volume (3 sets)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High RT volume (6 sets)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (CT)
Number of subjects: 34
Study: 27689944

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment (0.67 mg/m2/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 27
Study: 27978848

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Programme (HeLP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25422193

Group type: EXPERIMENTAL
Intervention: Telephone and postal intervention
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Telephone intervention only
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Postal intervention only
Number of subjects: 923

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 923
Study: 22038464

Group type: EXPERIMENTAL
Intervention: CloA (750 mL/day, 802.5 mg polyphenols)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control Beverage (CB, isocaloric equivalent to CloA, 750 mL/day)
Number of subjects: 68
Study: 20482344

Group type: EXPERIMENTAL
Intervention: Orthopedic maxillary expansion (OME)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surgically assisted rapid palatal expansion (SARME)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 30
Study: 16769180

Group type: EXPERIMENTAL
Intervention: 30 mg oral THC (10 mg three times a day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 90 mg oral THC (30 mg three times a day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16246942

Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum for half an hour after a refluxogenic meal
Number of subjects: 31

Group type: COMPARATOR
Intervention: No chewing gum (control)
Number of subjects: 31
Study: 11897207

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Simvastatin 20 mg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 1732

Group type: COMPARATOR
Intervention: Simvastatin 80 mg
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 1732

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1732
Study: 9471927

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/d
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/d
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Alendronate 20/0 mg/d
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: Alendronate 1 mg/d
Number of subjects: 447

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study: 7607932

Group type: EXPERIMENTAL
Intervention: Nicotinamide 80 mg/kg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nicotinamide 90 mg/kg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nicotinamide 100 mg/kg/day
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nicotinamide (various doses)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nicotinamide (increased doses)
Number of subjects: 11
Study: 2369475

Group type: COMPARATOR
Intervention: Epinephrine alone (group 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin and epinephrine (group 2)
Number of subjects: 28
Study: 7017496

Group type: EXPERIMENTAL
Intervention: Guacetisal (preparation B)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (preparation A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Guaiacol carbonate (preparation C)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Bromexine, acetylsalicylic acid, and codeine phosphate (preparation D)
Number of subjects: 57
Study: 31720835

Group type: EXPERIMENTAL
Intervention: Lenvatinib (LEN)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sorafenib (SOR)
Number of subjects: 168
Study: 30901487

Group type: EXPERIMENTAL
Intervention: Clonidine 75 μg every third hour up to a maximum of four doses, then 75 μg twice daily until delirium free for 2 days, discharge, or a maximum of 7 days of treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 27925308

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated stents
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Calcified lesions
Number of subjects: 827

Group type: COMPARATOR
Intervention: Non-calcified lesions
Number of subjects: 827

Group type: EXPERIMENTAL
Intervention: Propensity-score matched subgroups
Number of subjects: 827
Study: 25623393

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg plus methotrexate (MTX)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab plus methotrexate (MTX)
Number of subjects: 592
Study: 23322512

Group type: EXPERIMENTAL
Intervention: 1,25(OH)₂D in vitro
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D (7,000 IU daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21859318

Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays (Group A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays supplemented with in-office bleaching with 9% hydrogen peroxide (Group B)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Home whitening for two weeks with 16% carbamide peroxide in custom-made trays supplemented with in-office bleaching with 27% hydrogen peroxide (Group C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 36
Study: 19122356

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g/day)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sulbactam/Ampicillin (6 g/day)
Number of subjects: 102
Study: 21038666

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/d
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 16286164

Group type: EXPERIMENTAL
Intervention: Low-dose laser
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: High-dose laser
Number of subjects: 298

Group type: COMPARATOR
Intervention: Sham procedure (placebo)
Number of subjects: 298
Study: 11991463

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations
Number of subjects: 137

Group type: COMPARATOR
Intervention: Nonbonded amalgam restorations
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Bonded amalgam restorations in nonretentive cavities
Number of subjects: 137
Study: 10214567

Group type: EXPERIMENTAL
Intervention: ADCON-L anti-adhesion barrier gel
Number of subjects: 50

Group type: COMPARATOR
Intervention: T1-weighted axial MR images
Number of subjects: 50
Study: 7783536

Group type: EXPERIMENTAL
Intervention: 30 mg prednisone added to the current daily dose, tapering off to baseline over 18 weeks
Number of subjects: 156

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 156
Study: 2215615

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 mg twice a day) and colestipol (10 g three times a day)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Niacin (1 g four times a day) and colestipol (10 g three times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy (placebo or colestipol if LDL cholesterol was elevated)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lovastatin and colestipol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Niacin and colestipol
Number of subjects: 120
Study: 633688

Group type: EXPERIMENTAL
Intervention: Patient Advocacy Group
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Halo Group
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Placebo Group
Number of subjects: 412

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 412
Study: 11952190

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate
Number of subjects: 136

Group type: COMPARATOR
Intervention: Expectancy
Number of subjects: 136
Study: 30427963

Group type: EXPERIMENTAL
Intervention: Synthetic bone graft (Osteon, Dentium)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Deproteinized bovine bone (Bio-Oss)
Number of subjects: 13
Study: 26695932

Group type: EXPERIMENTAL
Intervention: Once per week (OPW) delivery of family-based childhood obesity programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice per week (TPW) delivery of family-based childhood obesity programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attendance
Number of subjects: 0
Study: 24429536

Group type: EXPERIMENTAL
Intervention: Zinc supplements twice daily
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Zinc supplements
Number of subjects: 450
Study: 22664560

Group type: EXPERIMENTAL
Intervention: Duodenal-jejunal bypass (DJB)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 18
Study: 20664386

Group type: EXPERIMENTAL
Intervention: 20-microgram ethinyl estradiol/100-microgram levonorgestrel
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: 30-microgram ethinyl estradiol/150-microgram levonorgestrel
Number of subjects: 226

Group type: COMPARATOR
Intervention: Inconsistent OCP use or nonuse
Number of subjects: 226
Study: 18584469

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) system for daily reports of withdrawal, craving, and negative mood for 7 days after quitting smoking
Number of subjects: 378

Group type: COMPARATOR
Intervention: Pencil and paper questionnaires (Minnesota Nicotine Withdrawal Scale, Questionnaire on Smoking Urges, Center for Epidemiological Studies‐Depression) completed a week after the target quit date
Number of subjects: 378
Study: 15920934

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum (Freedent White)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Xanthan gum-based artificial saliva (Xialine)
Number of subjects: 65
Study: 11998936

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch anastomosis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Straight anastomosis
Number of subjects: 42
Study: 10422532

Group type: EXPERIMENTAL
Intervention: Complex wrist and forearm posture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrogoniometer measurements
Number of subjects: 0